LEESBURG, Va., April 28, 2016 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (Nasdaq:KTWO) (the "Company" or "K2M"), a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine and minimally invasive spine technologies and techniques, hosted more than 120 of the world’s leading spine surgeons for its annual Meeting of Minds™ in Chicago, Illinois on April 22–23, 2016. Meeting of Minds offers spine surgeons a premiere, world-class curriculum in the latest approaches and techniques for the operative treatment of spinal disorders.
This meeting provided attendees with opportunities to participate in more than 60 hands-on product training demonstrations and case presentations, as well as interactive discussions on key complex spine issues in pediatric, adolescent, and adult reconstruction, including minimally invasive techniques, sagittal plane balance correction, trauma, tumor, and scoliosis.
“The Meeting of Minds was a spectacular collection of complex spine lectures,” said Peter Newton, MD, Chief of the Division of Orthopedics & Scoliosis at Rady Children’s Hospital-San Diego, clinical professor at UC San Diego School of Medicine, and a course chair at this year’s meeting. “From adults to pediatrics and open to MIS, the topics were comprehensively covered. I appreciate K2M’s commitment to supporting surgeon education.”
The 2016 Meeting of Minds was chaired by distinguished leaders in spine surgery such as Oheneba Boachie-Adjei, MD, FOCOS Orthopedic Hospital, Accra, Ghana, and Professor and Former Chief Emeritus of the Scoliosis Service, Hospital for Special Surgery, New York; Harry Shufflebarger, MD, Miami Children’s Hospital, Florida; Thomas Errico, MD, New York University, New York; and Peter Newton, MD, Rady Children’s Hospital-San Diego, California. Meeting faculty also included 18 other leading spine surgeons.
In addition to providing comprehensive medical education, Meeting of Minds offered surgeons exposure to K2M’s innovative product portfolio, adding to their clinical knowledge and expertise of implants and surgical techniques.
“K2M’s Meeting of Minds is currently the best venue available for spine surgeons to gain new knowledge and learn new technologies. I look forward to my third meeting next year,” said Ricky R. Kalra, MD, a neurosurgeon and Chief Resident at the University of Utah Hospital in Salt Lake City, who was an attendee at this year’s meeting.
“The K2M Meeting of Minds is an excellent conference for both the young and seasoned spine surgeon,” said Brian Morelli, MD, an orthopedic surgeon in the Spine & Scoliosis Center at Stony Brook School of Medicine and an assistant professor in the Department of Orthopaedics at Stony Brook University in New York, who also was an attendee at the meeting. “It is a real treat to have such a collection of top internationally recognized spine surgeons as the course instructors. Hands-on breakout sessions with the faculty give an intimate view of how these surgeons apply the advanced technologies offered by K2M. I leave this meeting with a few more "tools in the box" and clearly see how this will help me in delivering high quality patient care. I look forward to the offerings of the 2017 meeting.”
“Our foundation has been built on a commitment to complex spine," said John Kostuik, MD, K2M Chief Medical Officer and Co-founder of K2M, and Professor Emeritus at Johns Hopkins University. "Our culture is built on a relentless commitment to innovation focused on groundbreaking technologies aimed at helping surgeons improve patient outcomes.”
“K2M is committed to becoming the global industry leader in complex spine and minimally invasive surgery medical education, advancing the knowledge of health care industry professionals on the latest procedures and technologies with the ultimate goal of improving patients’ lives,” stated Eric Major, President and CEO of K2M. “Our annual Meeting of Minds, which offers surgeon training on deformity and minimally invasive products, and the many other educational opportunities provided by K2M have a positive impact within our industry by providing health care professionals with opportunities and support in training, education, and quality patient care.”
K2M Group Holdings, Inc. is a global medical device company focused on designing, developing and commercializing innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most difficult and challenging spinal pathologies. K2M has leveraged these core competencies to bring to market an increasing number of products for patients suffering from degenerative spinal conditions. These technologies and techniques, in combination with a robust product pipeline, enable the Company to favorably compete in the global spinal surgery market. Additional information is available online at www.K2M.com.
This press release contains forward-looking statements that reflect current views with respect to, among other things, operations and financial performance. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward looking statements are subject to various risks and uncertainties including, among other things: our ability to achieve or sustain profitability; our ability to successfully demonstrate the merits of our technologies; pricing pressure from our competitors, hospitals and changes in third-party coverage and reimbursement; competition and our ability to develop and commercialize new products; aggregation of hospital purchasing from collaboration and consolidation; hospitals and other healthcare providers may be unable to obtain adequate coverage and reimbursement for procedures performed using our products; the safety and efficacy of our products is not yet supported by long-term clinical data; our dependence on a limited number of third-party suppliers; our ability to maintain and expand our network of direct sales employees, independent sales agencies and international distributors; the proliferation of physician-owned distributorships; concentration of sales from a limited number of spinal systems or products that incorporate these technologies; loss of the services of key members of our senior management, consultants or personnel; ability to enhance our product offerings through our research and development efforts; failure to properly manage our anticipated growth; acquisitions of or investments in new or complementary businesses, products or technologies; ability to train surgeons on the safe and appropriate use of our products; requirements to maintain high levels of inventory; impairment of our goodwill or intangible assets; disruptions in our information technology systems; any disruption or delays in operations at our facilities, including our new headquarters facility; or an ability to ship a sufficient number of our products to meet demand; ability to strengthen our brand; fluctuations in insurance cost and availability; extensive governmental regulation in the United States and foreign jurisdictions; failure to obtain or maintain regulatory approvals and clearances; requirements for new 510(k) clearances, premarket approvals or new or amended CE Certificates of Conformity; medical device reporting regulations in the United States and foreign jurisdictions, voluntary corrective actions or agency enforcement actions; a recall of our products, withdrawal or restrictions on our products or the discovery of serious safety issues with our products; possible enforcement action if we engage in improper marketing or promotion of our products; the misuse or off-label use of our products; delays or failures in any future clinical trials; the results of clinical trials; procurement and use of allograft bone tissue; environmental laws and regulations; compliance by us or our sales representatives with FDA regulations or fraud and abuse laws; U.S. legislative or regulatory healthcare reforms; medical device tax provisions in the healthcare reform laws; our need to generate significant sales to become profitable; potential fluctuations in sales volumes and our results of operations may fluctuate over the course of the year; uncertainty in our future capital needs; failure to comply with restrictions in our revolving credit facility; continuing worldwide economic instability; our inability to protect our intellectual property rights; our reliance on patent rights that we either license from others or have obtained through assignments; our patent litigation; the outcome of potential claims that we, our employees, our independent sales agencies or our distributors have wrongfully used or disclosed alleged trade secrets or are in breach of non-competition or non-solicitation agreements with our competitors; potential product liability lawsuits; operating risks relating to our international operations; foreign currency fluctuations; our ability to comply with the Foreign Corrupt Practices Act and similar laws associated with our activities outside the United States; possible conflicts of interest with our large shareholders; increased costs and additional regulations and requirements as a result of becoming a public company; our ability to implement and maintain effective internal control over financial reporting in the future; the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions we may make; and other risks and uncertainties, including those described under the section entitled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC, as such factors may be updated from time to time in our periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and our filings with the SEC. We operate in a very competitive and challenging environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this release.
We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.
The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward looking statements and you should not place undue reliance on our forward-looking statements.
Media Contact: Zeno Group on behalf of K2M Group Holdings, Inc. Marcie Kohenak, 202-965-7811 Marcie.Kohenak@ZenoGroup.com Investor Contact: Westwicke Partners on behalf of K2M Group Holdings, Inc. Mike Piccinino, CFA, 443-213-0500 K2M@westwicke.com